{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:12:19Z","timestamp":1793743939859,"version":"4.6.1"},"reference-count":269,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Systemic sclerosis (SSc, scleroderma) is a multifaceted rare connective tissue disease whose pathogenesis is dominated by immune dysregulation, small vessel vasculopathy, impaired angiogenesis, and both cutaneous and visceral fibrosis. Microvascular impairment represents the initial event of the disease, preceding fibrosis by months or years and accounting for the main disabling and\/or life-threatening clinical manifestations, including telangiectasias, pitting scars, periungual microvascular abnormalities (e.g., giant capillaries, hemorrhages, avascular areas, ramified\/bushy capillaries) clinically detectable by nailfold videocapillaroscopy, ischemic digital ulcers, pulmonary arterial hypertension, and scleroderma renal crisis. Despite a variety of available treatment options, treatment of SSc-related vascular disease remains problematic, even considering SSc etherogenity and the quite narrow therapeutic window. In this context, plenty of studies have highlighted the great usefulness in clinical practice of vascular biomarkers allowing clinicians to assess the evolution of the pathological process affecting the vessels, as well as to predict the prognosis and the response to therapy. The current narrative review provides an up-to-date overview of the main candidate vascular biomarkers that have been proposed for SSc, focusing on their main reported associations with characteristic clinical vascular features of the disease.<\/jats:p>","DOI":"10.3390\/ijms24044097","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T03:56:07Z","timestamp":1676865367000},"page":"4097","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9275-7593","authenticated-orcid":false,"given":"Bianca Saveria","family":"Fioretto","sequence":"first","affiliation":[{"name":"Section of Anatomy and Histology, Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6352-0175","authenticated-orcid":false,"given":"Irene","family":"Rosa","sequence":"additional","affiliation":[{"name":"Section of Anatomy and Histology, Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[{"name":"Section of Internal Medicine, Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy"},{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2744-8625","authenticated-orcid":false,"given":"Eloisa","family":"Romano","sequence":"additional","affiliation":[{"name":"Section of Internal Medicine, Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3956-8480","authenticated-orcid":false,"given":"Mirko","family":"Manetti","sequence":"additional","affiliation":[{"name":"Section of Anatomy and Histology, Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy"},{"name":"Imaging Platform, Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2019.02.010","article-title":"Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis","volume":"209","author":"Korman","year":"2019","journal-title":"Transl. Res."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Asano, Y. (2020). The pathogenesis of systemic sclerosis: An understanding based on a common pathologic cascade across multiple organs and additional organ-specific pathologies. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092687"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/art.37988","article-title":"Review: Evidence that systemic sclerosis is a vascular disease","volume":"65","author":"Kahaleh","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Romano, E., Rosa, I., Fioretto, B.S., Matucci-Cerinic, M., and Manetti, M. (2021). New insights into profibrotic myofibroblast formation in systemic sclerosis: When the vascular wall becomes the enemy. Life, 11.","DOI":"10.3390\/life11070610"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"788250","DOI":"10.3389\/fmed.2021.788250","article-title":"Management of endothelial dysfunction in systemic sclerosis: Current and developing strategies","volume":"8","author":"Oliveira","year":"2021","journal-title":"Front. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"849086","DOI":"10.3389\/fmed.2022.849086","article-title":"Endothelial dysfunction in systemic lupus erythematosus and systemic sclerosis: A common trigger for different microvascular diseases","volume":"9","author":"Moschetti","year":"2022","journal-title":"Front. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.amjms.2022.02.014","article-title":"Assessment of kidney involvement in systemic sclerosis: From scleroderma renal crisis to subclinical renal vasculopathy","volume":"364","author":"Gigante","year":"2022","journal-title":"Am. J. Med. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Cole, A., Ong, V.H., and Denton, C.P. (2022). Renal disease and systemic sclerosis: An update on scleroderma renal crisis. Clin. Rev. Allergy Immunol.","DOI":"10.1007\/s12016-022-08945-x"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.autrev.2014.12.001","article-title":"Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis","volume":"14","author":"Chora","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/annrheumdis-2016-210229","article-title":"Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis","volume":"76","author":"Manetti","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Utsunomiya, A., Oyama, N., and Hasegawa, M. (2020). Potential biomarkers in systemic sclerosis: A literature review and update. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113388"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/1346-8138.13156","article-title":"Biomarkers in systemic sclerosis: Their potential to predict clinical courses","volume":"43","author":"Hasegawa","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3389\/fimmu.2019.01078","article-title":"Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment","volume":"10","author":"Guenther","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3389\/fimmu.2018.02045","article-title":"Vascular leaking, a pivotal and early pathogenetic event in systemic sclerosis: Should the door be closed?","volume":"9","author":"Bruni","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/cvr\/cvv154","article-title":"Selectins: Initiators of leucocyte adhesion and signaling at the vascular wall","volume":"107","author":"McEver","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/glycob\/cwx105","article-title":"Selectins in cancer immunity","volume":"28","author":"Borsig","year":"2018","journal-title":"Glycobiology"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hasegawa, M., Asano, Y., Endo, H., Fujimoto, M., Goto, D., Ihn, H., Inoue, K., Ishikawa, O., Kawaguchi, Y., and Kuwana, M. (2014). Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: A multicentre, prospective, observational study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0088150"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1046\/j.1365-2141.1996.7562378.x","article-title":"Soluble L-selectin in the connective tissue diseases","volume":"95","author":"Blann","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Dunne, J.V., Van Eeden, S.F., and Keen, K.J. (2012). L-selectin and skin damage in systemic sclerosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044814"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0923-1811(00)00108-0","article-title":"Elevated serum levels of soluble L-selectin in patients with systemic sclerosis declined after intravenous injection of lipo-prostaglandin E1","volume":"25","author":"Inaoki","year":"2001","journal-title":"J. Dermatol. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1046\/j.1365-2249.2001.01514.x","article-title":"Elevated serum L-selectin levels and decreased L-selectin expression on CD8+lymphocytes in systemic sclerosis","volume":"124","author":"Shimada","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.thromres.2021.12.027","article-title":"The role of P-selectin in cancer-associated thrombosis and beyond","volume":"213","author":"Yeini","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11926-022-01076-4","article-title":"Update on biomarkers of vasculopathy in juvenile and adult myositis","volume":"24","author":"McLellan","year":"2022","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1590\/S0100-879X2004000900018","article-title":"Correlation between serum E-selectin levels and panoramic nailfold capillaroscopy in systemic sclerosis","volume":"37","author":"Valim","year":"2004","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4236","article-title":"Early systemic sclerosis: Marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers","volume":"15","author":"Valentini","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wautier, J.L., and Wautier, M.P. (2022). Vascular permeability in diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073645"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/rheumatology\/36.12.1270","article-title":"Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: Enhancement by inflammatory cytokines","volume":"36","author":"Ihn","year":"1997","journal-title":"Br. J. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/clin.1993.1100","article-title":"Circulating intercellular adhesionmolecule-1 in patients with systemic sclerosis","volume":"68","author":"Sfikakis","year":"1993","journal-title":"Clin. Immunol. Immunopathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/annrheumdis-2011-200143","article-title":"Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis","volume":"71","author":"Avouac","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"R55","DOI":"10.1186\/ar4217","article-title":"Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis","volume":"15","author":"Avouac","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Pendergrass, S.A., Hayes, E., Farina, G., Lemaire, R., Farber, H.W., Whitfield, M.L., and Lafyatis, R. (2010). Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012106"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s10067-018-4081-7","article-title":"Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations","volume":"37","author":"Thakkar","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"843671","DOI":"10.3389\/fcell.2022.843671","article-title":"The roles of junctional adhesion molecules (JAMs) in cell migration","volume":"10","author":"Wang","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"183299","DOI":"10.1016\/j.bbamem.2020.183299","article-title":"Physiological functions of junctional adhesion molecules (JAMs) in tight junctions","volume":"1862","author":"Hartmann","year":"2020","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/art.37712","article-title":"Differential expression of junctional adhesion molecules in different stages of systemic sclerosis","volume":"65","author":"Manetti","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Romano, E., Rosa, I., Fioretto, B.S., Matucci-Cerinic, M., and Manetti, M. (2022). Increased circulating soluble junctional adhesion molecules in systemic sclerosis: Association with peripheral microvascular impairment. Life, 12.","DOI":"10.3390\/life12111790"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.4049\/jimmunol.1000556","article-title":"Junctional adhesion molecule-C is a soluble mediator of angiogenesis","volume":"185","author":"Rabquer","year":"2010","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/qjmed\/91.8.561","article-title":"Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma","volume":"91","author":"Stratton","year":"1998","journal-title":"QJM"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/00015550152572976","article-title":"Systemic sclerosis-related Raynaud\u2019s phenomenon: Effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels","volume":"81","author":"Mittag","year":"2001","journal-title":"Acta Derm. Venereol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10067-004-0987-3","article-title":"Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: Relationship to organ systemic involvement","volume":"24","author":"Klimiuk","year":"2005","journal-title":"Clin. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/ard.2007.080424","article-title":"Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension","volume":"67","author":"Iannone","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_43","first-page":"455","article-title":"Vascular endothelial growth factor (VEGF)\u2013Key factor in normal and pathological angiogenesis","volume":"59","author":"Melincovici","year":"2018","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/1573397114666180809121005","article-title":"The role of vascular endothelial growth factor in systemic sclerosis","volume":"15","author":"Flower","year":"2019","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1582-4934.2010.01027.x","article-title":"Mechanisms in the loss of capillaries in systemic sclerosis: Angiogenesis versus vasculogenesis","volume":"14","author":"Manetti","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/01.RES.0000134644.89917.96","article-title":"Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis","volume":"95","author":"Distler","year":"2004","journal-title":"Circ. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1002\/art.23968","article-title":"Angiogenesis in systemic sclerosis: Impaired expression of vascular endothelial growth factor receptor 1 in endothelial progenitor-derived cells under hypoxic conditions","volume":"58","author":"Avouac","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3899\/jrheum.080516","article-title":"Abnormalities in the regulators of angiogenesis in patients with scleroderma","volume":"36","author":"Hummers","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/ar596","article-title":"Angiogenic and angiostatic factors in systemic sclerosis: Increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers","volume":"4","author":"Distler","year":"2002","journal-title":"Arthritis Res."},{"key":"ref_50","first-page":"S46","article-title":"Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis","volume":"29","author":"Riccieri","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_51","first-page":"1529","article-title":"Elevated vascular endothelial growth factor in systemic sclerosis","volume":"30","author":"Choi","year":"2003","journal-title":"J. Rheumatol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Papaioannou, A.I., Zakynthinos, E., Kostikas, K., Kiropoulos, T., Koutsokera, A., Ziogas, A., Koutroumpas, A., Sakkas, L., Gourgoulianis, K.I., and Daniil, Z.D. (2009). Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis. BMC Pulm. Med., 9.","DOI":"10.1186\/1471-2466-9-18"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/1756-185X.12130","article-title":"Dysregulation of angiogenic homeostasis in systemic sclerosis","volume":"16","author":"Farouk","year":"2013","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.autrev.2014.10.009","article-title":"A PRISMA-driven systematic review for predictive risk factors of digital ulcers in systemic sclerosis patients","volume":"14","author":"Silva","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_55","first-page":"S127","article-title":"Predictive value of vascular disease biomarkers for digital ulcers in systemic sclerosis patients","volume":"33","author":"Silva","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s10067-016-3219-8","article-title":"Impaired angiogenesis as a feature of digital ulcers in systemic sclerosis","volume":"35","author":"Silva","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2478\/v10039-011-0025-z","article-title":"Peripheral blood mononuclear cells frompatientswith systemic sclerosis spontaneously secrete increased amounts of vascular endothelial growth factor (VEGF) already in the early stage of the disease","volume":"56","author":"Bielecki","year":"2011","journal-title":"Adv. Med. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/rheumatology\/kep154","article-title":"The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis","volume":"48","author":"Solanilla","year":"2009","journal-title":"Rheumatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1365-2133.2009.09567.x","article-title":"Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis","volume":"162","author":"Jinnin","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Schoonderwoerd, M.J.A., Goumans, M.T.H., and Hawinkels, L.J.A.C. (2020). Endoglin: Beyond the endothelium. Biomolecules, 10.","DOI":"10.3390\/biom10020289"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10456-008-9101-9","article-title":"Endoglin in angiogenesis and vascular diseases","volume":"11","author":"Goumans","year":"2008","journal-title":"Angiogenesis"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/rheumatology\/ken100","article-title":"Disturbed angiogenesis in systemic sclerosis: High levels of soluble endoglin","volume":"47","author":"Wipff","year":"2008","journal-title":"Rheumatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11010-021-04294-z","article-title":"The role of endoglin and its soluble form in pathogenesis of preeclampsia","volume":"477","author":"Petousis","year":"2022","journal-title":"Mol. Cell. Biochem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000093846","article-title":"A clue for telangiectasis in systemic sclerosis: Elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease","volume":"213","author":"Fujimoto","year":"2006","journal-title":"Dermatology"},{"key":"ref_65","first-page":"969383","article-title":"Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure","volume":"2010","author":"Garces","year":"2010","journal-title":"Int. J. Rheumatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3389\/fphys.2018.00587","article-title":"Biomarkers for pulmonary vascular remodeling in systemic sclerosis: A pathophysiological approach","volume":"9","author":"Odler","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"125632","DOI":"10.1155\/2013\/125632","article-title":"Endothelin-1 levels in scleroderma patients: A pilot study","volume":"2013","author":"Cozzani","year":"2013","journal-title":"ISRN Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00296-008-0829-8","article-title":"Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis","volume":"29","author":"Quintana","year":"2009","journal-title":"Rheumatol. Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4103\/2229-5178.93484","article-title":"Endothelin-1 in systemic sclerosis","volume":"3","author":"Aghaei","year":"2012","journal-title":"Indian Dermatol. Online J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10067-009-1288-7","article-title":"Capillary dimension measured by computer-based digitalized image correlated with plasma endothelin-1 levels in patients with systemic sclerosis","volume":"29","author":"Kim","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.advms.2020.12.007","article-title":"Metabolic mediators determine the association of antinuclear antibody subtypes with specific clinical symptoms in systemic sclerosis","volume":"66","author":"Stochmal","year":"2021","journal-title":"Adv. Med. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3899\/jrheum.081030","article-title":"Raynaud\u2019s phenomenon and plasma endothelin: Correlations with capillaroscopic patterns in systemic sclerosis","volume":"36","author":"Sulli","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00296-013-2861-6","article-title":"Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy","volume":"34","author":"Kawashiri","year":"2014","journal-title":"Rheumatol. Int."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10067-013-2354-8","article-title":"Serum endothelin-1 and NT-proBNP, but not ADMA, endoglin and TIMP-1 levels, reflect impaired right ventricular function in patients with systemic sclerosis","volume":"33","author":"Bienias","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.humpath.2010.05.018","article-title":"Endothelin-1 expression in scleroderma renal crisis","volume":"42","author":"Mouthon","year":"2011","journal-title":"Hum. Pathol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.ajkd.2009.02.015","article-title":"Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney","volume":"54","author":"Dhaun","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/qjmed\/hct111","article-title":"Targeting the endothelin axis in scleroderma renal crisis: Rationale and feasibility","volume":"106","author":"Penn","year":"2013","journal-title":"QJM"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00296-017-3797-z","article-title":"Endothelin-1, \u03b1-Klotho, 25(OH) Vit D levels and severity of disease in scleroderma patients","volume":"37","author":"Hajialilo","year":"2017","journal-title":"Rheumatol. Int."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar4457","article-title":"Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis","volume":"16","author":"Kill","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","article-title":"Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis","volume":"190","author":"Becker","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3899\/jrheum.150061","article-title":"Autoantibodies against endothelin 1 type a receptor are strong predictors of digital ulcers in systemic sclerosis","volume":"42","author":"Avouac","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrm2183","article-title":"Molecular regulation of angiogenesis and lymphangiogenesis","volume":"8","author":"Adams","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2006.08.015","article-title":"Alternative splicing in angiogenesis: The vascular endothelial growth factor paradigm","volume":"249","author":"Ladomery","year":"2006","journal-title":"Cancer Lett."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2017.05.024","article-title":"The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review","volume":"16","author":"Mostmans","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1161\/CIRCRESAHA.111.242057","article-title":"Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis","volume":"109","author":"Manetti","year":"2011","journal-title":"Circ. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tcm.2012.05.011","article-title":"Impaired angiogenesis in systemic sclerosis: The emerging role of the antiangiogenic VEGF(165)b splice variant","volume":"21","author":"Manetti","year":"2011","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1136\/annrheumdis-2012-203183","article-title":"Increased plasma levels of the VEGF165b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis","volume":"72","author":"Manetti","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"102584","DOI":"10.1016\/j.autrev.2020.102584","article-title":"Pentraxin 3: A promising therapeutic target for autoimmune diseases","volume":"19","author":"Wu","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3899\/jrheum.080343","article-title":"Increased serum pentraxin 3 in patients with systemic sclerosis","volume":"36","author":"Iwata","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.38953","article-title":"Elevated levels of pentraxin 3 in systemic sclerosis: Associations with vascular manifestations and defective vasculogenesis","volume":"67","author":"Shirai","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Borghini, A., Manetti, M., Nacci, F., Bellando-Randone, S., Guiducci, S., Matucci-Cerinic, M., Ibba-Manneschi, L., and Weber, E. (2015). Systemic sclerosis sera impair angiogenic performance of dermal microvascular endothelial cells: Therapeutic implications of cyclophosphamide. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0130166"},{"key":"ref_92","first-page":"102","article-title":"Prediction of organ involvement in systemic sclerosis by serum biomarkers and peripheral endothelial function","volume":"36","author":"Kawashiri","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10067-016-3483-7","article-title":"Low serum fibroblast growth factor 2 levels not accompanied by increased serum pentraxin 3 levels in patients with systemic sclerosis","volume":"36","author":"Yayla","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.yexcr.2005.11.015","article-title":"Antiangiogenesis in cancer therapy\u2014Endostatin and its mechanisms of action","volume":"312","author":"Folkmann","year":"2006","journal-title":"Exp. Cell Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/1529-0131(200004)43:4<889::AID-ANR21>3.0.CO;2-5","article-title":"Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis","volume":"43","author":"Hebbar","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1155\/MI.2005.144","article-title":"Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients","volume":"2005","author":"Waszczykowska","year":"2005","journal-title":"Mediat. Inflamm."},{"key":"ref_97","first-page":"508","article-title":"Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis\u2014Association with pulmonary involvement","volume":"24","author":"Waszczykowska","year":"2006","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13075-015-0756-5","article-title":"Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: An observational study","volume":"17","author":"Reiseter","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_99","first-page":"37","article-title":"Different contributions of angiostatin and endostatin in angiogenesis impairment in systemic sclerosis: A cohort study","volume":"34","author":"Almeida","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.mvr.2017.06.003","article-title":"Angiogenic and angiostatic factors in renal scleroderma-associated vasculopathy","volume":"114","author":"Gigante","year":"2017","journal-title":"Microvasc. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/iwj.12882","article-title":"Serum level of endostatin and digital ulcers in systemic sclerosis patients","volume":"15","author":"Gigante","year":"2018","journal-title":"Int. Wound J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e12449","DOI":"10.1111\/micc.12449","article-title":"In systemic sclerosis, microvascular and hands digital arteries damage correlates with serum levels of endostatin","volume":"25","author":"Gigante","year":"2018","journal-title":"Microcirculation"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13075-023-02989-w","article-title":"Proteomic aptamer analysis reveals serum markers that characterize preclinical systemic sclerosis (SSc) Patients at risk for progression toward definite SSc","volume":"25","author":"Bellocchi","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Kanno, Y. (2019). The role of fibrinolytic regulators in vascular dysfunction of systemic sclerosis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030619"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1002\/art.22861","article-title":"Antiangiogenic plasma activity in patients with systemic sclerosis","volume":"56","author":"Drinane","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"543","DOI":"10.5114\/ada.2017.72459","article-title":"Circulating angiostatin serum level in patients with systemic sclerosis","volume":"34","year":"2017","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"103881","DOI":"10.1016\/j.mvr.2019.103881","article-title":"Imbalanced serum levels of Ang1, Ang2 and VEGF in systemic sclerosis: Integrated effects on microvascular reactivity","volume":"125","author":"Cutolo","year":"2019","journal-title":"Microvasc. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s13300-022-01326-9","article-title":"The role of angiopoietins in neovascular diabetes-related retinal diseases","volume":"13","author":"Mendivil","year":"2022","journal-title":"Diabetes Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"727451","DOI":"10.3389\/fphys.2021.727451","article-title":"Distinct metalloproteinase expression and functions in systemic sclerosis and fibrosis: What we know and the potential for intervention","volume":"12","author":"Leong","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s10875-012-9735-7","article-title":"Matrix metalloproteinases: A review of their structure and role in systemic sclerosis","volume":"32","author":"Peng","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1185\/030079905X30680","article-title":"The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension","volume":"21","author":"Giannelli","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Waszczykowska, A., Podg\u00f3rski, M., Waszczykowski, M., Gerlicz-Kowalczuk, Z., and Jurowski, P. (2020). Matrix metalloproteinases MMP-2 and MMP-9, their inhibitors TIMP-1 and TIMP-2, vascular endothelial growth factor and sVEGFR-2 as predictive markers of ischemic retinopathy in patients with systemic sclerosis\u2014Case series report. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228703"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2011-200837","article-title":"Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: Correlation with severity of skin and pulmonary fibrosis and vascular damage","volume":"71","author":"Manetti","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"164134","DOI":"10.1155\/2008\/164134","article-title":"Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure","volume":"2008","author":"Elias","year":"2008","journal-title":"Mediat. Inflamm."},{"key":"ref_115","first-page":"6416514","article-title":"Plasma glycosaminoglycan profiles in systemic sclerosis: Associations with MMP-3, MMP-10, TIMP-1, TIMP-2, and TGF-beta","volume":"2020","author":"Kucharz","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"ref_116","first-page":"133","article-title":"A new avenue in the pathogenesis of systemic sclerosis: The molecular interface between the endothelial and the nervous systems","volume":"37","author":"Romano","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Romano, E., Rosa, I., Fioretto, B.S., Matucci-Cerinic, M., and Manetti, M. (2022). Circulating neurovascular guidance molecules and their relationship with peripheral microvascular impairment in systemic sclerosis. Life, 12.","DOI":"10.3390\/life12071056"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/annrheumdis-2015-207483","article-title":"Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis","volume":"75","author":"Romano","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2002591","DOI":"10.1183\/13993003.02591-2020","article-title":"Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: Machine learning on proteomics from the DETECT cohort","volume":"57","author":"Bauer","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3899\/jrheum.160791","article-title":"Evidence for a derangement of the microvascular system in patients with a very early diagnosis of systemic sclerosis","volume":"44","author":"Chora","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13075-015-0749-4","article-title":"Plexin-D1\/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis","volume":"17","author":"Mazzotta","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1136\/annrheumdis-2018-213239","article-title":"Slit2\/Robo4 axis may contribute to endothelial cell dysfunction and angiogenesis disturbance in systemic sclerosis","volume":"77","author":"Romano","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3389\/fimmu.2020.00346","article-title":"Semaphorins in angiogenesis and autoimmune diseases: Therapeutic targets?","volume":"11","author":"Wojcikiewicz","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard.2010.136929","article-title":"Preliminary criteria for the very early diagnosis of systemic sclerosis: Results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group","volume":"70","author":"Avouac","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"119803","DOI":"10.1016\/j.lfs.2021.119803","article-title":"A comprehensive review of sirtuins: With a major focus on redox homeostasis and metabolism","volume":"282","author":"Shahgaldi","year":"2021","journal-title":"Life Sci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10522-020-09873-z","article-title":"Sirtuins family as a target in endothelial cell dysfunction: Implications for vascular ageing","volume":"21","author":"Zhang","year":"2020","journal-title":"Biogerontology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3389\/fonc.2019.01516","article-title":"Role of sirtuins in tumor angiogenesis","volume":"9","author":"Edatt","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/jcp.27200","article-title":"Emerging role of SIRT3 in endothelial metabolism, angiogenesis, and cardiovascular disease","volume":"234","author":"He","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Manetti, M., Rosa, I., Fioretto, B.S., Matucci-Cerinic, M., and Romano, E. (2022). Decreased serum levels of SIRT1 and SIRT3 correlate with severity of skin and lung fibrosis and peripheral microvasculopathy in systemic sclerosis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051362"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"R96","DOI":"10.1530\/VB-21-0010","article-title":"Interleukin role in the regulation of endothelial cell pathological activation","volume":"3","author":"Carbone","year":"2021","journal-title":"Vasc. Biol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fimmu.2019.02025","article-title":"The role of IL-1 family cytokines in the pathogenesis of systemic sclerosis","volume":"10","author":"Xu","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Shima, Y. (2021). Cytokines involved in the pathogenesis of ssc and problems in the development of anti-cytokine therapy. Cells, 10.","DOI":"10.3390\/cells10051104"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/jcp.2004.019224","article-title":"Alterations of mononuclear inflammatory cells, CD4\/CD8+ T cells, interleukin 1\u03b2, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis","volume":"58","author":"Hussein","year":"2005","journal-title":"J. Clin. Pathol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e1045","DOI":"10.1002\/cti2.1045","article-title":"Analysis of serum interleukin(IL)-1\u03b1, IL-1\u03b2 and IL-18 in patients with systemic sclerosis","volume":"8","author":"Lin","year":"2019","journal-title":"Clin. Transl. Immunol."},{"key":"ref_135","first-page":"19","article-title":"Proinflammatory cytokines (IL-12 and IL-18) in immune rheumatic diseases: Relation with disease activity and autoantibodies production","volume":"10","author":"Mosaad","year":"2003","journal-title":"Egypt. J. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/1346-8138.13252","article-title":"Serum levels of interleukin-18-binding protein isoform a: Clinical association with inflammation and pulmonary hypertension in systemic sclerosis","volume":"43","author":"Nakamura","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1136\/ard.2010.148247","article-title":"Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement","volume":"70","author":"Manetti","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10067-011-1686-5","article-title":"Serum IL-33 levels are raised in patients with systemic sclerosis: Association with extent of skin sclerosis and severity of pulmonary fibrosis","volume":"30","author":"Yanaba","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/annrheumdis-2012-201553","article-title":"Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis","volume":"72","author":"Terras","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Iannazzo, F., Pellicano, C., Colalillo, A., Ramaccini, C., Romaniello, A., Gigante, A., and Rosato, E. (2022). Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement. Clin. Exp. Med.","DOI":"10.1007\/s10238-022-00864-7"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"104344","DOI":"10.1016\/j.mvr.2022.104344","article-title":"IL33 and sST2 serum level in systemic sclerosis microvascular involvement","volume":"142","author":"Pellicano","year":"2022","journal-title":"Microvasc. Res."},{"key":"ref_142","first-page":"328","article-title":"Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis","volume":"24","author":"Hasegawa","year":"1997","journal-title":"J. Rheumatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/cei.13651","article-title":"Body mass index and adipokines\/cytokines dysregulation in systemic sclerosis","volume":"206","author":"Iannone","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1111\/jocd.15133","article-title":"Peripheral blood IL-6 levels in systemic sclerosis patients: Correlation between IL-6 levels and clinical phenotypes","volume":"21","author":"Lin","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/rheumatology\/ket131","article-title":"Relationship between interleukin-6 and cardiac involvement in systemic sclerosis","volume":"52","author":"Jurisic","year":"2013","journal-title":"Rheumatology"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00296-022-05250-w","article-title":"Serum levels of interleukin 17 and 22 in patients with systemic sclerosis: A single-center cross-sectional study","volume":"43","author":"Kardum","year":"2023","journal-title":"Rheumatol. Int."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/RHU.0000000000000947","article-title":"Serum interleukin 35 levels in systemic sclerosis and relationship with clinical features","volume":"26","author":"Yayla","year":"2020","journal-title":"J. Clin. Rheumatol."},{"key":"ref_148","first-page":"2273","article-title":"Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease","volume":"54","author":"Tomcik","year":"2015","journal-title":"Rheumatology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/art.30318","article-title":"Interferon and alternative activation of monocyte\/macrophages in systemic sclerosis-associated pulmonary arterial hypertension","volume":"63","author":"Christmann","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_150","first-page":"44","article-title":"IL-17, IL-6 and IFN-\u03b3 in systemic sclerosis patients","volume":"53","author":"Nicolau","year":"2015","journal-title":"Rom. J. Intern. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"151964","DOI":"10.1016\/j.imbio.2020.151964","article-title":"Increased levels of the soluble oncostatin M receptor (sOSMR) and glycoprotein 130 (sgp130) in systemic sclerosis patients and associations with clinical parameters","volume":"225","author":"Dantas","year":"2020","journal-title":"Immunobiology"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"706","DOI":"10.5114\/aoms.2019.84738","article-title":"Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis","volume":"15","author":"Robak","year":"2019","journal-title":"Arch. Med. Sci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/1346-8138.15508","article-title":"Interleukin (IL)-17F and IL-17E are related to fibrosis and vasculopathy in systemic sclerosis","volume":"47","author":"Fukayama","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_154","first-page":"519","article-title":"IL-16 expression is increased in the skin and sera of patients with systemic sclerosis","volume":"59","author":"Kawabata","year":"2020","journal-title":"Rheumatology"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13075-020-02218-8","article-title":"Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension","volume":"22","author":"Guggino","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4081\/reumatismo.2014.774","article-title":"Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor \u03b2 in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension","volume":"66","author":"Stefanantoni","year":"2015","journal-title":"Reumatismo"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13075-022-02734-9","article-title":"Cytokine signatures differentiate systemic sclerosis patients at high versus low risk for pulmonary arterial hypertension","volume":"24","author":"Kolstad","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/82_2010_21","article-title":"Chemokines in angiogenesis","volume":"341","author":"Dimberg","year":"2010","journal-title":"Chemokine Syst. Exp. Clin. Hematol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41584-019-0323-6","article-title":"Chemokines in rheumatic diseases: Pathogenic role and therapeutic implications","volume":"15","author":"Miyabe","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1161\/ATVBAHA.108.162925","article-title":"Chemokines as mediators of neovascularization","volume":"28","author":"Keeley","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.4049\/jimmunol.177.4.2651","article-title":"CCL2 regulates angiogenesis via activation of Ets-1 transcription factor","volume":"177","author":"Stamatovic","year":"2006","journal-title":"J. Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/0008-5472.CAN-12-0653","article-title":"Twist1 induces CCL2 and recruits macrophages to promote angiogenesis","volume":"73","author":"Ardi","year":"2013","journal-title":"Cancer Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/rheumatology\/kem313","article-title":"CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis-a longitudinal study","volume":"47","author":"Antonelli","year":"2008","journal-title":"Rheumatology"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10875-014-0037-0","article-title":"Early systemic sclerosis: Serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels","volume":"34","author":"Vettori","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"ref_165","first-page":"S44","article-title":"CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: The correlation with SSc clinical features and the effect of prostaglandin E1 treatment","volume":"30","author":"Bandinelli","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/ard.2006.067967","article-title":"Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?","volume":"67","author":"Carulli","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/art.40171","article-title":"CCL2 in the circulation predicts long-term progression of interstitial lung disease in patients with early systemic sclerosis: Data from two independent cohorts","volume":"69","author":"Wu","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.18632\/oncotarget.6708","article-title":"CCL3 promotes angiogenesis by dysregulation of miR-374b\/ VEGF-A axis in human osteosarcoma cells","volume":"7","author":"Liao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/carcin\/bgu218","article-title":"CCL5\/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment","volume":"36","author":"Wang","year":"2015","journal-title":"Carcinogenesis"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"812431","DOI":"10.3389\/fimmu.2022.812431","article-title":"Functional roles of chemokine receptor CCR2 and its ligands in liver disease","volume":"13","author":"She","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2133.2009.09507.x","article-title":"CCL13 is a promising diagnostic marker for systemic sclerosis","volume":"162","author":"Yanaba","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2133.2011.10330.x","article-title":"Serum CCL13 levels in patients with systemic sclerosis and controls","volume":"165","author":"Gambichler","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.yexcr.2018.09.023","article-title":"CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer","volume":"372","author":"Benkheil","year":"2018","journal-title":"Exp. Cell Res."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Korbecki, J., Grochans, S., Gutowska, I., Barczak, K., and Baranowska-Bosiacka, I. (2020). CC chemokines in a tumor: A review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207619"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1756-185X.14103","article-title":"Association of serum CCL20 levels with pulmonary vascular involvement and primary biliary cholangitis in patients with systemic sclerosis","volume":"24","author":"Ikawa","year":"2021","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3892\/ijo.2017.4003","article-title":"CCL21\/CCR7 interaction promotes cellular migration and invasion via modulation of the MEK\/ERK1\/2 signaling pathway and correlates with lymphatic metastatic spread and poor prognosis in urinary bladder cancer","volume":"51","author":"Xiong","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/art.34452","article-title":"Role of the CCL21 and CCR7 pathways in rheumatoid arthritis angiogenesis","volume":"64","author":"Pickens","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/art.40534","article-title":"CCL21 as a potential serum biomarker for pulmonary arterial hypertension in systemic sclerosis","volume":"70","author":"Hesselstrand","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"991743","DOI":"10.3389\/fimmu.2022.991743","article-title":"Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension","volume":"13","author":"Didriksen","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"6195004","DOI":"10.1155\/2022\/6195004","article-title":"Elevated serum levels of CCL23 are associated with poor outcome after resection of biliary tract cancer","volume":"2022","author":"Roderburg","year":"2022","journal-title":"Mediat. Inflamm."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00403-010-1078-8","article-title":"Serum CCL23 levels are increased in patients with systemic sclerosis","volume":"303","author":"Yanaba","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"27725","DOI":"10.18632\/oncotarget.9486","article-title":"Platelet factor 4 is produced by subsets of myeloid cells in premetastatic lung and inhibits tumor metastasis","volume":"8","author":"Jian","year":"2017","journal-title":"Oncotarget"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jdermsci.2021.07.006","article-title":"Contribution to the peripheral vasculopathy and endothelial cell dysfunction by CXCL4 in systemic sclerosis","volume":"104","author":"Jiang","year":"2021","journal-title":"J. Dermatol. Sci."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"Affandi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13075-016-1203-y","article-title":"Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease","volume":"18","author":"Volkmann","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3899\/jrheum.160833","article-title":"Proteomic analysis of sera from individuals with diffuse cutaneous systemic sclerosis reveals a multianalyte signature associated with clinical improvement during imatinib mesylate treatment","volume":"44","author":"Haddon","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10238-016-0437-y","article-title":"CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc)","volume":"17","author":"Valentini","year":"2017","journal-title":"Clin. Exp. Med."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00403-013-1431-9","article-title":"Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis","volume":"306","author":"Ichimura","year":"2014","journal-title":"Arch. Dermatol. Res."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"R18","DOI":"10.1186\/ar3242","article-title":"Dysregulated expression of MIG\/CXCL9, IP-10\/CXCL10 and CXCL16 and their receptors in systemic sclerosis","volume":"13","author":"Rabquer","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/art.40243","article-title":"Earliest phase of systemic sclerosis typified by increased levels of inflammatory proteins in the serum","volume":"69","author":"Cossu","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.medcli.2021.12.006","article-title":"Utility of cytokines CXCL4, CXCL8 and GDF15 as biomarkers in systemic sclerosis","volume":"159","year":"2022","journal-title":"Med. Clin."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fimmu.2011.00082","article-title":"Pathological role of fractalkine\/CX3CL1 in rheumatic diseases: A unique chemokine with multiple functions","volume":"2","author":"Jones","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cytogfr.2017.12.001","article-title":"Fractalkine and placental growth factor: A duet of inflammation and angiogenesis in cardiovascular disorders","volume":"39","author":"Skoda","year":"2018","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/ard.2003.018705","article-title":"Up regulated expression of fractalkine\/CX3CL1 and CX3CR1 in patients with systemic sclerosis","volume":"64","author":"Hasegawa","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_195","first-page":"527","article-title":"Increased serum fractalkine in systemic sclerosis. Down-regulation by prostaglandin E1","volume":"26","author":"Sicinska","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13075-017-1271-7","article-title":"Increased serum levels of fractalkine and mobilisation of CD34+CD45- endothelial progenitor cells in systemic sclerosis","volume":"19","author":"Benyamine","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00403-019-01993-y","article-title":"Altered serum level of metabolic and endothelial factors in patients with systemic sclerosis","volume":"312","author":"Stochmal","year":"2020","journal-title":"Arch. Dermatol. Res."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00403-019-01893-1","article-title":"The role of adipokines in systemic sclerosis: A missing link?","volume":"311","author":"Stochmal","year":"2019","journal-title":"Arch. Dermatol. Res."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"578966","DOI":"10.3389\/fphys.2020.578966","article-title":"Adipokines: New potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases","volume":"11","author":"Recinella","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Brezovec, N., Kojc, N., Erman, A., Hladnik, M., Stergar, J., Milani\u010d, M., Tom\u0161i\u010d, M., \u010cu\u010dnik, S., Sodin-\u0160emrl, S., and Per\u0161e, M. (2022). Molecular and cellular markers in chlorhexidine-induced peritoneal fibrosis in mice. Biomedicines, 10.","DOI":"10.3390\/biomedicines10112726"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00393-016-0172-5","article-title":"Meta-analysis of circulating adiponectin, leptin, and resistin levels in systemic sclerosis","volume":"76","author":"Lee","year":"2017","journal-title":"Z. Rheumatol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1468-3083.2011.04077.x","article-title":"Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis: Significance of serum adiponectin levels in SSc","volume":"26","author":"Masui","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1600-0625.2011.01310.x","article-title":"Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients: Letter to the editor","volume":"20","author":"Arakawa","year":"2011","journal-title":"Exp. Dermatol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"R102","DOI":"10.1186\/ar3827","article-title":"Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: Potential utility as a biomarker?","volume":"14","author":"Lakota","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/1756-185X.12332","article-title":"Relationship between adiponectin, leptin, IGF-1 and total lipid peroxides plasma concentrations in patients with systemic sclerosis: Possible role in disease development","volume":"19","author":"Kucharz","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5114\/ada.2018.75809","article-title":"Clinical associations of serum leptin and leptin\/adiponectin ratio in systemic sclerosis","volume":"36","author":"Sawicka","year":"2019","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/art.40193","article-title":"Brief report: Association of elevated adipsin levels with pulmonary arterial hypertension in systemic sclerosis","volume":"69","author":"Korman","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00403-020-02172-0","article-title":"Epoprostenol up-regulates serum adiponectin level in patients with systemic sclerosis: Therapeutic implications","volume":"313","author":"Stochmal","year":"2021","journal-title":"Arch. Dermatol. Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/2277-9175.156526","article-title":"Leptin and its cardiovascular effects: Focus on angiogenesis","volume":"4","author":"Tahergorabi","year":"2015","journal-title":"Adv. Biomed. Res."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s100670170053","article-title":"A decreased serum leptin level in patients with systemic sclerosis","volume":"20","author":"Kotulska","year":"2001","journal-title":"Clin. Rheumatol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1756-185X.2012.01755.x","article-title":"Serum leptin, resistin and TNF-\u03b1 levels in patients with systemic sclerosis: The role of adipokines in scleroderma","volume":"15","author":"Pehlivan","year":"2012","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1183\/09031936.00159911","article-title":"Leptin and regulatory t-lymphocytes in idiopathic pulmonary arterial hypertension","volume":"40","author":"Huertas","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_213","first-page":"156","article-title":"Circulating adipokines and organ involvement in patients with systemic sclerosis","volume":"40","author":"Katulska","year":"2015","journal-title":"Acta Reumatol. Port."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/14397595.2016.1193106","article-title":"Serum adipokines levels in patients with systemic sclerosis: A meta-analysis","volume":"27","author":"Zhao","year":"2017","journal-title":"Mod. Rheumatol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00296-013-2880-3","article-title":"Serum resistin levels: A possible correlation with pulmonary vascular involvement in patients with systemic sclerosis","volume":"34","author":"Masui","year":"2014","journal-title":"Rheumatol. Int."},{"key":"ref_216","first-page":"144","article-title":"Resistin: A possible biomarker of organ involvement in systemic sclerosis patients?","volume":"35","author":"Sawicka","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10238-021-00756-2","article-title":"Serum resistin is predictive marker of development of new digital ulcers in systemic sclerosis","volume":"22","author":"Pellicano","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/1381612827666210927164935","article-title":"Therapeutic potential of Galectin-1 and Galectin-3 in autoimmune diseases","volume":"28","author":"He","year":"2022","journal-title":"Curr. Pharm. Des."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"650605","DOI":"10.3389\/fphar.2021.650605","article-title":"Circulating Galectin-1 and Galectin-3 in sera from patients with systemic sclerosis: Associations with clinical features and treatment","volume":"12","author":"Sundblad","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/1756-185X.12288","article-title":"Circulating galectin-1 concentrations in systemic sclerosis: Potential contribution to digital vasculopathy","volume":"19","author":"Yanaba","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10067-013-2346-8","article-title":"Serum galectin-3 level in systemic sclerosis","volume":"33","author":"Koca","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3899\/jrheum.110755","article-title":"Serum levels of galectin-3: Possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis","volume":"39","author":"Taniguchi","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/1346-8138.12810","article-title":"Serum vaspin levels: A possible correlation with digital ulcers in patients with systemic sclerosis","volume":"42","author":"Miura","year":"2015","journal-title":"J. Dermatol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"551","DOI":"10.5114\/ada.2018.79104","article-title":"Visfatin and chemerin levels correspond with inflammation and might reflect the bridge between metabolism, inflammation and fibrosis in patients with systemic sclerosis","volume":"36","author":"Sawicka","year":"2019","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/rheumatology\/keu479","article-title":"Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis","volume":"54","author":"Akamata","year":"2015","journal-title":"Rheumatology"},{"key":"ref_226","first-page":"223","article-title":"Serum chemerin in systemic sclerosis: A novel marker of early diffuse disease?","volume":"35","author":"Chighizola","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/ard-2022-223237","article-title":"Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis","volume":"82","author":"Sanges","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/BOR.0000000000000907","article-title":"Type 1 Interferon activation in systemic sclerosis: A biomarker, a target or the culprit","volume":"34","author":"Kakkar","year":"2022","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1055\/a-1801-2055","article-title":"Circulating thrombomodulin: Release mechanisms, measurements, and levels in diseases and medical procedures","volume":"6","author":"Boron","year":"2022","journal-title":"TH Open"},{"key":"ref_230","first-page":"1440","article-title":"Plasma thrombomodulin as a marker of vascular damage in systemic sclerosis","volume":"22","author":"Seigneur","year":"1995","journal-title":"J. Rheumatol."},{"key":"ref_231","first-page":"1444","article-title":"Increase in plasma thrombomodulin in patients with systemic sclerosis","volume":"20","author":"Soma","year":"1993","journal-title":"J. Rheumatol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/ard.59.2.132","article-title":"Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension","volume":"59","author":"Stratton","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0002-9343(96)80070-2","article-title":"Plasma levels of thrombomodulin in pulmonary hypertension","volume":"101","author":"Cacoub","year":"1996","journal-title":"Am. J. Med."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14737159.2019.1571911","article-title":"Soluble CD163 is a potential biomarker in systemic sclerosis","volume":"19","author":"Matsushita","year":"2019","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00296-010-1691-z","article-title":"Serum levels of soluble CD163 in patients with systemic sclerosis","volume":"32","author":"Nakayama","year":"2012","journal-title":"Rheumatol. Int."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5152\/eurjrheum.2016.15088","article-title":"Serum soluble CD163 and its association with various disease parameters in patients with systemic sclerosis","volume":"3","author":"Hassan","year":"2016","journal-title":"Eur. J. Rheumatol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"8509583","DOI":"10.1155\/2018\/8509583","article-title":"Soluble CD163 as a potential biomarker in systemic sclerosis","volume":"2018","author":"Frantz","year":"2018","journal-title":"Dis. Markers"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10067-012-1972-x","article-title":"Increased serum levels of soluble CD163 in patients with scleroderma","volume":"31","author":"Shimizu","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"R69","DOI":"10.1186\/ar4246","article-title":"High serum sCD163\/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis","volume":"15","author":"Bielecki","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2478\/v10039-012-0076-9","article-title":"Increased release of soluble CD163 by the peripheral blood mononuclear cells is associated with worse prognosis in patients with systemic sclerosis","volume":"58","author":"Bielecki","year":"2013","journal-title":"Adv. Med. Sci."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"113983","DOI":"10.1016\/j.biopha.2022.113983","article-title":"CD147 and MMPs as key factors in physiological and pathological processes","volume":"157","author":"Asgari","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s10067-012-1949-9","article-title":"Increased serum soluble CD147 levels in patients with systemic sclerosis: Association with scleroderma renal crisis","volume":"31","author":"Yanaba","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12016-012-8312-4","article-title":"N-TproBNP as biomarker in systemic sclerosis","volume":"43","author":"Schioppo","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1002\/art.11345","article-title":"N-Terminal pro-Brain Natriuretic Peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers","volume":"48","author":"Allanore","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3899\/jrheum.090997","article-title":"Comparison of Brain Natriuretic Peptide (BNP) and NT-ProBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis","volume":"37","author":"Cavagna","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/art.23187","article-title":"High N-Terminal pro-Brain Natriuretic Peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis","volume":"58","author":"Allanore","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/eurheartj\/ehi891","article-title":"Role of N-Terminal Brain Natriuretic Peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension","volume":"27","author":"Williams","year":"2006","journal-title":"Eur. Heart J."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s10067-010-1494-3","article-title":"Left atrial volume and N-Terminal Pro-B type Natriuretic Peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis","volume":"29","author":"Dimitroulas","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"ref_249","first-page":"106","article-title":"Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry","volume":"35","author":"Chung","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.clinbiochem.2010.03.011","article-title":"NT-ProBNP levels in systemic sclerosis: Association with clinical and laboratory abnormalities","volume":"43","author":"Oravec","year":"2010","journal-title":"Clin. Biochem."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10067-008-0837-9","article-title":"Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis","volume":"27","author":"Bienias","year":"2008","journal-title":"Clin. Rheumatol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/acr.22547","article-title":"cardiac biomarkers in systemic sclerosis: Contribution of high-sensitivity cardiac troponin in addition to N-Terminal pro-Brain Natriuretic Peptide","volume":"67","author":"Avouac","year":"2015","journal-title":"Arthritis Care Res."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0954-6111(03)00254-3","article-title":"Significance of plasma N-Terminal pro-Brain Natriuretic Peptide in patients with systemic sclerosis-related pulmonary arterial hypertension","volume":"97","author":"Mukerjee","year":"2003","journal-title":"Respir. Med."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"105287","DOI":"10.1016\/j.jbspin.2021.105287","article-title":"Diagnostic value of cardiac natriuretic peptide on pulmonary hypertension in systemic sclerosis: A systematic review and meta-analysis","volume":"89","author":"Zhang","year":"2022","journal-title":"Joint Bone Spine"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"482","DOI":"10.7326\/0003-4819-94-4-482","article-title":"Increased factor VIII\/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud\u2019s phenomenon","volume":"94","author":"Kahaleh","year":"1981","journal-title":"Ann. Intern. Med."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/ard.55.2.122","article-title":"Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud\u2019s phenomenon and systemic sclerosis","volume":"55","author":"Herrick","year":"1996","journal-title":"Ann. Rheum. Dis."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/ar295","article-title":"Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma)","volume":"3","author":"Scheja","year":"2001","journal-title":"Arthritis Res."},{"key":"ref_258","first-page":"414","article-title":"Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato\/polymyositis","volume":"26","author":"Kumanovics","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/1076029617736382","article-title":"The plasma levels of ADAMTS-13, von Willebrand Factor, VWFpp, and fibrin-related markers in patients with systemic sclerosis having thrombosis","volume":"24","author":"Habe","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/rheumatology\/kes068","article-title":"Baseline vWF factor predicts the development of elevated pulmonary artery pressure in systemic sclerosis","volume":"51","author":"Barnes","year":"2012","journal-title":"Rheumatology"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.20081880","article-title":"Maresins: Novel macrophage mediators with potent antiinflammatory and proresolving actions","volume":"206","author":"Serhan","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"104366","DOI":"10.1016\/j.mvr.2022.104366","article-title":"Maresin1 is a predictive marker of new digital ulcers in systemic sclerosis patients","volume":"142","author":"Pellicano","year":"2022","journal-title":"Microvasc. Res."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1002\/art.22263","article-title":"Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: Failure of association in systemic sclerosis endothelial cells","volume":"54","author":"Margheri","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/postgradmedj-2018-135839","article-title":"SuPAR, an emerging biomarker in kidney and inflammatory diseases","volume":"94","author":"Hamie","year":"2018","journal-title":"Postgrad. Med. J."},{"key":"ref_265","first-page":"1799","article-title":"Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: Possible association with microvascular abnormalities and extent of fibrosis","volume":"53","author":"Toldi","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_266","doi-asserted-by":"crossref","unstructured":"Butt, S., Jeppesen, J.L., Iversen, L.V., Fenger, M., Eugen-Olsen, J., Andersson, C., and Jacobsen, S. (2021). Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247256"},{"key":"ref_267","doi-asserted-by":"crossref","unstructured":"Hysa, E., Campitiello, R., Sammor\u00ec, S., Gotelli, E., Cere, A., Pesce, G., Pizzorni, C., Paolino, S., Sulli, A., and Smith, V. (2023). Specific autoantibodies and microvascular damage progression assessed by nailfold videocapillaroscopy in systemic sclerosis: Are there peculiar associations? An update. Antibodies, 12.","DOI":"10.3390\/antib12010003"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s10067-019-04863-0","article-title":"Vascular biomarkers and digital ulcerations in systemic sclerosis: Results from a randomized controlled trial of oral treprostinil (DISTOL-1)","volume":"39","author":"Mecoli","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/BOR.0000000000000827","article-title":"Biomarkers in systemic sclerosis: Mechanistic insights into pathogenesis and treatment","volume":"33","author":"Arron","year":"2021","journal-title":"Curr. Opin. Rheumatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/4097\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:39:59Z","timestamp":1760121599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/4097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":269,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24044097"],"URL":"https:\/\/doi.org\/10.3390\/ijms24044097","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]}}}